XENE
Xenon Pharmaceuticals Inc.
$67.71
+0.41 (+0.61%)
At close · Jul 15
Market Cap
$6.47B
Shares
96,665,550
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| Investor Event Transcript | 2026-06-30 | — | |
| 8-K | 2026-06-03 | 2026-06-02 | |
| 8-K | 2026-05-07 | — | |
| 10-Q | 2026-05-07 | 2026-03-31 | |
| DEF 14A | 2026-04-22 | — | |
| 8-K | 2026-04-13 | 2026-04-07 | |
| 8-K | 2026-03-13 | — | |
| 8-K | 2026-03-12 | 2026-03-10 | |
| 8-K | 2026-03-09 | — | |
| 8-K | 2026-02-27 | — | |
| 8-K | 2026-02-26 | — | |
| 10-K | 2026-02-26 | 2025-12-31 | |
| 8-K | 2025-12-01 | 2025-11-24 | |
| 8-K | 2025-11-03 | — | |
| 10-Q | 2025-11-03 | 2025-09-30 | |
| 8-K/A | 2025-10-17 | 2025-10-15 | |
| 8-K | 2025-10-16 | 2025-10-15 | |
| 10-Q | 2025-08-11 | 2025-06-30 | |
| 8-K | 2025-08-11 | — | |
| 8-K | 2025-07-03 | 2025-06-30 | |
| 8-K | 2025-06-05 | 2025-06-04 | |
| 8-K | 2025-05-12 | — | |
| 10-Q | 2025-05-12 | 2025-03-31 | |
| DEF 14A | 2025-04-24 | — | |
| 8-K | 2025-03-17 | 2025-03-14 | |
| 8-K | 2025-03-05 | 2025-03-03 | |
| 10-K | 2025-02-27 | 2024-12-31 | |
| 8-K | 2025-02-27 | 2025-02-24 | |
| 8-K | 2025-01-17 | — | |
| 10-Q | 2024-11-12 | 2024-09-30 | |
| 8-K | 2024-11-12 | — | |
| 10-Q | 2024-08-08 | 2024-06-30 | |
| 8-K | 2024-08-08 | — | |
| 8-K | 2024-06-05 | 2024-06-04 | |
| 10-Q | 2024-05-09 | 2024-03-31 | |
| 8-K | 2024-05-09 | — | |
| DEF 14A | 2024-04-26 | — | |
| 8-K | 2024-04-19 | 2024-04-15 | |
| 8-K | 2024-03-08 | — | |
| 8-K | 2024-02-29 | — | |
| 10-K | 2024-02-29 | 2023-12-31 | |
| 8-K | 2023-11-30 | 2023-11-29 | |
| 8-K | 2023-11-27 | — | |
| 8-K | 2023-11-09 | — | |
| 10-Q | 2023-11-08 | 2023-09-30 | |
| 8-K | 2023-11-08 | — | |
| 8-K | 2023-08-09 | — | |
| 10-Q | 2023-08-09 | 2023-06-30 | |
| 8-K | 2023-08-08 | — | |
| 8-K | 2023-06-02 | 2023-06-01 |
Showing 1–50 of 113 filings
Key facts
CIK
1582313
CUSIP
98420N105
13F (30d)
12 filings
12 filers
Visit website
Investor relations